Key Milestones Achieved and Future Plans Discussed in CorMedix (CRMD) Q1 2024 Earnings Call

Thursday, 9 May 2024, 15:00

CorMedix announced achievements in obtaining CMS approval for DefenCath, commencing commercial launch, initiating outpatient procurement contracts, and renewing financial facilities. Operating expense guidance, label expansion plans, and supply chain developments were discussed. Financial results showed increased expenses and net loss, but improved cash position supporting operations through anticipated profitability in 2024.
https://store.livarava.com/6276ddc7-0e15-11ef-a6c2-63e1980711b2.jpg
Key Milestones Achieved and Future Plans Discussed in CorMedix (CRMD) Q1 2024 Earnings Call

CorMedix (CRMD) Q1 2024 Earnings Call Highlights:

Key Achievements:

  • Obtained CMS approval for DefenCath and started inpatient commercial launch
  • Initiated outpatient procurement contracts and discussed label expansion plans
  • Submitted supplement for alternate manufacturer in the supply chain

Financial Results:

  • Net loss increased driven by higher operating expenses
  • Operating expenses rose, primarily due to growth and commercial launch costs
  • Net cash used in operations increased, but cash position improved to support operations

CorMedix aims for breakeven profitability in 2024, with a focus on commercial execution and financial flexibility.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe